Neoadjuvant pd-1 inhibitor Anlotinib chemotherapy safty efficacy
Showing 1 - 25 of >10,000
Neoadjuvent, PD-1 Inhibitor, Lung Cancer Trial in Xi'an (neoadjuvant PD-1 inhibitor, anlotinib combined with chemo)
Recruiting
- Neoadjuvent
- +4 more
- neoadjuvant PD-1 inhibitor, anlotinib combined with chemotherapy
-
Xi'an, ChinaTangdu Hospital, the Air Force Military University
May 26, 2022
Esophageal Squamous Cell Carcinoma Trial in Hangzhou (Cadonilimab combined Anlotinib)
Recruiting
- Esophageal Squamous Cell Carcinoma
- Cadonilimab combined Anlotinib
-
Hangzhou, Zhejiang, China2nd Affiliated Hospital, School of Medicine, Zhejiang University
Aug 6, 2023
Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and
Not yet recruiting
- Colorectal Neoplasms
-
Beijing, Xicheng Dis, ChinaBeijing Friendship Hospital, Capital medical University
Sep 5, 2023
Esophageal Carcinoma, Neoadjuvant Immunotherapy Trial in Beijing (PD-1 blockade, Albumin paclitaxel, Carboplatin/Nedaplatin)
Recruiting
- Esophageal Carcinoma
- Neoadjuvant Immunotherapy
- PD-1 blockade
- +2 more
-
Beijing, Beijing, ChinaQin li
Mar 8, 2023
Nasopharyngeal Carcinoma, Neoadjuvant Therapy, PD-1 Inhibitor Trial (PD-1 inhibitor+GP, GP)
Not yet recruiting
- Nasopharyngeal Carcinoma
- +2 more
- PD-1 inhibitor+GP
- GP
- (no location specified)
Jul 1, 2022
Disorder in Complete Remission in Response to Treatment Trial in Wuhan (Sintilimal Injection)
Recruiting
- Disorder in Complete Remission in Response to Treatment
- Sintilimal Injection
-
Wuhan, Hubei, ChinaRenmin Hospital of Wuhan University
Sep 28, 2022
Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy Trial in Wuhan (drug, procedure, radiation)
Not yet recruiting
- Head and Neck Squamous Cell Carcinoma
- Neoadjuvant Therapy
- 3cycles (Toripalimab + cetuximab)
- +2 more
-
Wuhan, Hebei, ChinaUnion Hospital, Tongji Medical College, Huazhong University of S
Aug 6, 2023
Rectal Tumors Trial in Nanning (Tislelizumab, Capecitabine, Oxaliplatin)
Recruiting
- Rectal Neoplasms
- Tislelizumab
- +4 more
-
Nanning, Guangxi, ChinaFirst Affiliated Hospital of Guangxi Medical University
Aug 27, 2023
Advanced Solid Tumor Trial in Beijing (Inosine 0.2g orally 3 times/day, PD-1/PD-L1 inhibitor ,chemo/targeting)
Completed
- Advanced Solid Tumor
- Inosine 0.2g orally 3 times/day
- PD-1/PD-L1 inhibitor ,chemotherapy/targeting
-
Beijing, Beijing, ChinaQin li
Mar 30, 2023
Nasopharyngeal Carcinoma Trial in Shanghai (Anti-EGFR and PD-1 inhibitor arm)
Recruiting
- Nasopharyngeal Carcinoma
- Anti-EGFR and PD-1 inhibitor arm
-
Shanghai, Shanghai, ChinaEye & ENT Hospital of Fudan University
Nov 26, 2023
Neoadjuvant Chemo, PD-1 Antibody, Radiotherapy Trial (neoadjuvant chemo combined with PD-1 antibody + radical radiotherapy)
Not yet recruiting
- Neoadjuvant Chemotherapy
- +3 more
- neoadjuvant chemotherapy combined with PD-1 antibody + radical radiotherapy
- (no location specified)
Sep 21, 2022
Rectal Tumors Malignant, Radiotherapy Trial in Beijing, Shenzhen (drug, radiation, combination product)
Not yet recruiting
- Rectal Neoplasms Malignant
- Radiotherapy
- Sintilimab
- +2 more
-
Beijing, Beijing, China
- +1 more
Jul 29, 2022
Locally Advanced Rectal Cancer Trial in Beijing (capecitabine, tislelizumab, thymalfasin)
Not yet recruiting
- Locally Advanced Rectal Cancer
- capecitabine
- +3 more
-
Beijing, China
- +1 more
Sep 21, 2023
HNSCC, Radiotherapy, PD-1 Trial in Guangzhou (PD-1inhibitor, concurrent chemoradiotherapy)
Recruiting
- HNSCC
- +2 more
- PD-1inhibitor
- concurrent chemoradiotherapy
-
Guangzhou, Guangdong, ChinaSun yat-sen memorial hospital
Aug 6, 2023
Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy Trial (neoadjuvant anti-PD-1 (Keytruda) plus chemo)
Not yet recruiting
- Esophageal Squamous Cell Carcinoma
- Neoadjuvant Chemoimmunotherapy
- neoadjuvant anti-PD-1 (Keytruda) plus chemotherapy
- (no location specified)
Feb 14, 2023
Overall Survival Trial in Qingdao (Anlotinib, PD-1 inhibitor)
Recruiting
- Overall Survival
- Anlotinib, PD-1 inhibitor
-
Qingdao, Shandong, China
- +1 more
Feb 23, 2022
Advanced Lung Squamous Cell Carcinoma Trial in Chengdu (low-dose radiation therapy and stereotactic body radiation therapy,
Not yet recruiting
- Advanced Lung Squamous Cell Carcinoma
- low-dose radiation therapy and stereotactic body radiation therapy
- +2 more
-
Chengdu, Sichuan, ChinaWest China Hospital of Sichuan University
Nov 13, 2023
Esophageal Tumor Metastatic, Esophageal Cancer Stage IVb Trial in Beijing (drug, biological, radiation)
Recruiting
- Esophageal Neoplasm Metastatic
- Esophageal Cancer Stage IVb
- TP (Paclitaxel with cisplatin or carboplatin) or PF (Fluoropyrimidine with cisplatin or carboplatin) regimen depended on investigator's choice.
- +3 more
-
Beijing, Beijing, ChinaCancer hospital, CAMS
Oct 19, 2023
Rectal Tumors Trial (procedure, drug, diagnostic test)
Not yet recruiting
- Rectal Neoplasms
- Arterial chemoembolization
- +4 more
- (no location specified)
Jun 26, 2022
Oral Squamous Cell Carcinoma Trial in Wuhan (Camrelizumab plus TP, TP)
Not yet recruiting
- Oral Squamous Cell Carcinoma
- Camrelizumab plus TP
- TP
-
Wuhan, Hubei, ChinaHospital of Stomatology, Wuhan University
Mar 22, 2023
Hepatocellular Cancer Trial in Shanghai (Anlotinib;Toripalimab)
Recruiting
- Hepatocellular Cancer
-
Shanghai, Shanghai, ChinaEastern hepatobilliary surgery hospital
Jul 7, 2022
Locally Advanced Hypopharyngeal Carcinoma Trial in Shanghai (drug, procedure, radiation)
Not yet recruiting
- Locally Advanced Hypopharyngeal Carcinoma
- three cycles (toripalimab + cetuximab + platinum)
- +2 more
-
Shanghai, Shanghai, ChinaEye & ENT Hospital of Fudan University
Nov 22, 2023
Nasopharyngeal Carcinoma Trial in Guangzhou (Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel),
Not yet recruiting
- Nasopharyngeal Carcinoma
- Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel)
- +3 more
-
Guangzhou, Guangdong, ChinaDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University C
Sep 17, 2022
Oropharyngeal Cancer Trial in Shanghai (Toxicities reduced treatment, Conventional treatment)
Recruiting
- Oropharyngeal Cancer
- Toxicities reduced treatment
- Conventional treatment
-
Shanghai, Shanghai, ChinaEye & ENT Hospital of Fudan University
Nov 26, 2023